Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2015-2022
Figure 4-2: Global - ADCETRIS Market (Billion US$), 2015-2022
Figure 4-3: Global - Kadcyla Market (Billion US$), 2015-2022
Figure 5-1: Global - ADCs Pipeline by Developing Organizations (%), 2016
Figure 5-2: Global – ADC Pipeline of Companies by Clinical Phase (%), 2016
Figure 5-3: Global - ADC Pipeline of Companies by Indication (%), 2016
Figure 5-4: Global - ADC Pipeline of Companies by Drug (%), 2016
Figure 5-5: Global – ADC Pipeline of Companies by Type of Linker (%), 2016
Figure 5-6: Global – ADC Pipeline of Companies by Mode of Action (%), 2016
Figure 5-7: Global – ADC Pipeline of Companies by Technology (%), 2016
Figure 5-8: Global – ADC Pipeline of Research Organization by Clinical Phase (%), 2016
Figure 5-9: Global – ADC Pipeline of Research Organization by Indication (%), 2016
Figure 5-10: Global – ADC Pipeline of Research Organization by Drug (%), 2016
Figure 5-11: Global – ADC Pipeline of Research Organization by Type of Linker (%), 2016
Figure 5-12: Global – ADC Pipeline of Research Organization by Mode of Action (%), 2016
Figure 10-1: Novartis AG - Net Sales Breakup by Business Segments (%), 2016
Figure 10-2: Novartis AG - Net Sales Breakup by Geography (%), 2016
Figure 10-3: Takeda Pharmaceutical Company Limited – Ethical Drugs Revenue Breakup by Geography (%), 2016
Figure 10-4: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2016
Figure 10-5: Astellas Pharma Inc. - Sales Breakup by Business Segments (%), 2016
Figure 10-6: Astellas Pharma Inc. - Sales Breakup by Geography (%), 2016

List of Tables:

Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 5-1: Global - ADC Pipeline of Companies
Table 5-2: Global - ADC Pipeline of Research Organization
Table 9-1: Strategic Collaborations in the ADC Industry (2014-2016)
Table 10-1: Top Companies by ADCs in Pipeline (2016)
Table 10-2: Seattle Genetics, Inc. - ADCs in Pipeline
Table 10-3: Seattle Genetics, Inc. - Key Financials (Million US$), 2013-2015
Table 10-4: Seattle Genetics, Inc. - Strengths and Weaknesses
Table 10-5: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
Table 10-6: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2013-2015
Table 10-7: F. Hoffman-La Roche Ltd. - Strengths and Weaknesses
Table 10-8: ImmunoGen, Inc. - ADCs in Pipeline
Table 10-9: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
Table 10-10: ImmunoGen, Inc. - Strengths and Weaknesses
Table 10-11: Bayer AG - ADCs in Pipeline
Table 10-12: Bayer AG - Key Financials (Million US$), 2013-2015
Table 10-13: Bayer AG - Strengths and Weaknesses
Table 10-14: Novartis AG - ADCs in Pipeline
Table 10-15: Novartis AG - Key Financials (Million US$), 2014-2016
Table 10-16: Novartis International AG - Strengths and Weaknesses
Table 10-17: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
Table 10-18: Millenium Pharmaceuticals - ADCs in Pipeline
Table 10-19: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 10-20: Immunomedics, Inc. - ADCs in Pipeline
Table 10-21: Immunomedics, Inc. - Key Financials (Million US$), 2014-2016
Table 10-22: Agensys, Inc. - ADCs in Pipeline
Table 10-23: Astellas Pharma Inc. - Key Financials (Million US$), 2014-2016
Table 10-24: Oxford BioTherapeutics - ADCs in Pipeline
Table 10-25: Concortis Biotherapeutics - ADCs in Pipeline
Table 10-26: NBE-Therapeutics - ADCs in Pipeline